Novel agents including antisense oligonucleotides and small interfering RNA targeting apolipoprotein(a) have been shown to reduce Lp(a) levels, and there are currently ongoing clinical trials to show their efficacy to prevent recurrent events in adults with ASCVD without severe kidney disease (NCT04023552 and NCT05581303).4 This evidence concerns the gene LPA and atherosclerosis.